High-dose therapy and autotransplantation in peripheral T-cell lymphoma and cutaneous T-cell lymphoma


Published: June 11, 2009
Abstract Views: 142
PDF: 325
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Peripheral T/NK-cell lymphomas (PTCL) comprise a rare and heterogeneous group of malignancies accounting for approximately 10-15% of all non- Hodgkin’s lymphomas (NHL) in Western countries. PTCL in general are characterized by an aggressive course and most studies revealed the T-cell phenotype as a negative prognostic marker.1-4 The international prognostic index (IPI) and T-cell specific prognostic index (PIT) have shown prognostic value in PTCL determining the outcome of patients with nodal peripheral T-cell lymphomas.5-8

Supporting Agencies


Reimer, P. (2009). High-dose therapy and autotransplantation in peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Hematology Meeting Reports (formerly Haematologica Reports), 3(1). https://doi.org/10.4081/hmr.v3i1.551

Downloads

Citations